How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,414 results for

Skin Conditions in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Comorbid conditions in lichen planopilaris: A retrospective data analysis of 334 patients Full Text available with Trip Pro

(6.3% vs. 0%; p = .023), hypothyroidism (24.3% vs. 12.8%; p = .028), and hirsutism (11.4% vs. 1.3%; p = .006). Negatively associated conditions were allergic rhinitis (15% vs. 24.4%; p = .046), diabetes mellitus type II (11.7% vs. 21.8%; p = .019), hyperlipidemia (38.6% vs. 52.6%; p = .024), vitamin D deficiency (50% vs. 65.4%; p = .014), depression (15.6% vs. 28.9%; p = .018), and sleep problems (7.5% vs. 29.5%; p < .001).Our study further emphasizes that dermatologists should screen patients (...) Comorbid conditions in lichen planopilaris: A retrospective data analysis of 334 patients Lichen planopilaris (LPP) is a rare, cicatricial, lymphocyte-mediated alopecia that is thought to have an autoimmune pathogenesis and possibly related to other autoimmune diseases. However, data are limited and studies that examine comorbid conditions are lacking.We sought to determine the prevalence of systemic comorbid conditions, nutritional deficiencies, psychological problems, and skin cancers

2018 International journal of women's dermatology

162. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min) Full Text available with Trip Pro

adults with diabetes mellitus and CKD stage 3b or higher (eGFR <45 mL/min), as defined by the recent KDIGO classification [ ]. The guideline does not cover interventions in patients with diabetes and CKD stages 1–2 to prevent or delay development of micro- or macro-albuminuria. 5.3.2. Conditions The guideline specifically covers the management of patients with diabetes mellitus and CKD stage 3b or higher (eGFR <45 mL/min), with a focus on three major areas: (i) selection of renal replacement modality (...) ERA-EDTA European Renal Association – European Dialysis and Transplant Association ERBP European Renal Best Practice MD Mean difference OR Odds ratio RR Relative risk 95% CI 95% Confidence interval 2. FOREWORD Diabetes mellitus is becoming increasingly prevalent and is considered a rapidly growing concern for healthcare systems. Besides the cardiovascular complications, diabetes mellitus is associated with chronic kidney disease (CKD). CKD in patients with diabetes can be caused by true diabetic

2015 European Renal Best Practice

163. Screening and Risk Stratification for Diabetic Foot Ulcers

Screening and Risk Stratification for Diabetic Foot Ulcers TITLE: Screening and Risk Stratification for Diabetic Foot Ulcers: A Review of Clinical Effectiveness, Cost-effectiveness, and Guidelines DATE: 30 October 2014 CONTEXT AND POLICY ISSUES The rising prevalence of diabetes mellitus (DM) and associated complications represent a global public health care problem and financial burden. 1,2 The estimated prevalence of DM in Canada was 6.8% (2.4 million) in 2009, a 230% increase from estimates (...) for Research and Evaluation AMSTAR Assessing the Methodological Quality of Systematic Reviews BOHTA Basque Office for Health Technology Assessment CDA Canadian Diabetes Association COI conflict of interest CONSORT Consolidated Standards of Reporting Trials CRD Centre for Reviews and Dissemination DFU diabetic foot ulcer DM diabetes mellitus DPY diabetic person years EO expert opinion FU follow-up HTA health technology assessment LOPS loss of protective sensation MA meta-analysis NHMRC National Health

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

164. Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children

procedures Signed Informed consent Exclusion Criteria: Patients tested positive for HBV, HCV, syphilis or HIV Patients with known underlying or concomitant medical conditions that may interfere with normal wound healing (e.g. systemic skin and connective tissue diseases, any kind of congenital defect of metabolism including insulin-dependent diabetes mellitus, Cushing syndrome or disease, scurvy, chronic hypothyroidism, congenital or acquired immunosuppressive condition, chronic renal failure, or chronic (...) to meshed STSG in adults and children with full-thickness Skin defects. Condition or disease Intervention/treatment Phase Skin Wound Biological: EHSG-KF Biological: STSG Phase 2 Detailed Description: This multicentre phase II clinical trial will target adults and children with fullt-thickness skin defects to elucidate the benefit of a tissue-engineered autologous skin substitute. Particular emphasis, apart from safety, will be placed on efficacy, e.g. scar quality, in comparison to meshed STSG. Study

2017 Clinical Trials

165. A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese

by (Responsible Party): Guixia Wang, First Hospital of Jilin University Study Details Study Description Go to Brief Summary: The purpose of this study is to determine the effect of GLP-1 receptor agonist on inducing diabetes remission in newly diagnosed type 2 diabetes who are overweight or obese Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: Exenatide Drug: BIAsp30 Drug: Metformin Phase 4 Detailed Description: Most of type 2 diabetes are characterized by being overweight (...) Identifier: Other Study ID Numbers: JLUEND001 First Posted: January 12, 2017 Last Update Posted: January 12, 2017 Last Verified: January 2017 Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Overweight Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Body Weight Signs and Symptoms Metformin Exenatide Insulin aspart, insulin aspart protamine drug combination 30:70 Insulin, Isophane Biphasic Insulins Insulin Aspart Glucagon

2017 Clinical Trials

166. Efficacy and Safety of Heberprot-P® in Patients With Advanced Diabetic Foot Ulcer in Dasman Diabetes Institute.

4, 2017 Last Update Posted: August 4, 2017 Last Verified: May 2016 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Additional relevant MeSH terms: Layout table for MeSH terms Diabetic Foot Foot Ulcer Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies Foot Diseases (...) amputation in Kuwait. Condition or disease Intervention/treatment Diabetic Foot Biological: Heberprot P Study Design Go to Layout table for study information Study Type : Observational Actual Enrollment : 50 participants Observational Model: Case-Only Time Perspective: Prospective Official Title: Efficacy and Safety of Heberprot-P® in Patients With Advanced Diabetic Foot Ulcer in Dasman Diabetes Institute. Demonstrative Study Study Start Date : December 2015 Actual Primary Completion Date : February 2016

2017 Clinical Trials

167. A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.

objective is to evaluate ocular and systemic safety and tolerability of BI 1467335 as well as whether BI 1467335 monotherapy has a potential to improve retinal lesions in patients with moderately severe Non-proliferative diabetic retinopathy (NPDR) (DRSS level 47) or severe Non-proliferative diabetic retinopathy (NPDR) (DRSS level 53), without Center-involved diabetic macular edema (CI-DME) Condition or disease Intervention/treatment Phase Diabetic Retinopathy Drug: BI 1467335 Drug: Placebo Phase 2 (...) meeting these criteria is provided in the patient information. Diagnosis of diabetes mellitus (type 1 or type 2): --Documented diabetes by American Diabetes Association (ADA) and/or World Health Organization criteria Glycosylated hemoglobin (HbA1c) ≤ 12% at screening Non-proliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME) in the study eye at screening with NPDR level 47 or level 53, as determined by the Central reading center (CRC) by using the DR severity

2017 Clinical Trials

168. A Systematic Review of Intravitreal Bevacizumab for the Treatment of Diabetic Macular Edema

for the Treatment of Diabetic Macular Edema established to update the search until May 1, 2012. Where possible, retrieval was limited to the human population for both searches. See Appendix 3 for the detailed search strategies. A supplemental review based on a non-systematic literature search was conducted to further identify evidence regarding the safety of intravitreal bevacizumab use in ocular conditions (Appendix 1). This search also considered observational studies and post-marketing surveillance safety (...) % was considered significant. The fixed effects model was applied to obtain summary statistics of pooled trials unless significant between-study heterogeneity was present, in which case the random effects model was used. Results Ten trials met the inclusion criteria: one of bevacizumab versus sham injections; 5 five versus laser therapy; 6-10 and four versus intravitreal triamcinolone. 11-14 Three studies included primarily patients with type 2 diabetes mellitus; 6,7,9 the remaining trials did not report

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

169. Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

with LVEF < 50%. Cardiovascular death in the total patient population. All-cause mortality in patients with LVEF < 50%. All cause mortality in the total patient population. To demonstrate the safety and tolerability of sotagliflozin in the total population in this study. Condition or disease Intervention/treatment Phase Heart Failure-Type 2 Diabetes Mellitus Drug: Sotagliflozin (SAR439954) Drug: Placebo Phase 3 Detailed Description: The estimated study duration for a given patient will be approximately (...) Inclusion criteria : Type 2 Diabetes Mellitus. Admitted to the hospital, or urgent heart failure visit for worsening heart failure. Prior diagnosis of heart failure (> 3 months). Prior chronic treatment for heart failure with a loop diuretic (eg furosemide, torsemide, bumetanide) for > 30 days. Randomized when hemodynamically stable, prior to hospital discharge or within 3 days of discharge. Brain natriuretic peptide (BNP) ≥150 pg/mL (≥450 pg/mL for patients with atrial fibrillation) or N-terminal B

2018 Clinical Trials

170. Exercise Training and Endothelial Function in Type 1 Diabetes

Update Posted: October 15, 2018 Last Verified: October 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by University Hospital, Lille: Type 1 diabetes endothelial function exercise training physical activity Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune (...) Exercise Training and Endothelial Function in Type 1 Diabetes Exercise Training and Endothelial Function in Type 1 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Exercise Training and Endothelial

2018 Clinical Trials

171. Preventing Diabetic Foot Ulcers Through Cleaner Feet

-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: No Keywords provided by VA Office of Research and Development: topical chlorhexidine prevention clinical trial Additional relevant MeSH terms: Layout table for MeSH terms Ulcer Diabetic Foot Foot Ulcer Pathologic Processes Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System (...) in Veterans with a recent history of a foot ulcer. Condition or disease Intervention/treatment Phase Diabetic Foot Ulcer Drug: Chlorhexidine Phase 2 Detailed Description: Population: Up to 200 Veterans at risk for diabetic foot ulcer recurrence Site: VA Maryland Health Care System (VAMHCS) Study Duration: Approximately 5 years Study Design: Randomized double-blind clinical trial comparing a) a daily foot care regimen with cloths containing 2% chlorhexidine to b) a daily foot care regimen with cloths

2018 Clinical Trials

172. Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

), improves hepatic insulin sensitivity, endogenous (hepatic) glucose production, de novo lipogenesis (DNL), HbA1c and lipid profiles. In addition, exploratory analysis with surrogate plasma biomarkers and imaging on liver fibrosis changes on with treatment will be performed. Condition or disease Intervention/treatment Phase Nonalcoholic Fatty Liver Disease (NAFLD) Type 2 Diabetes (T2DM) Drug: Lanifibranor Other: Placebo Phase 2 Detailed Description: The study is a two-arm (placebo, lanifibranor 800 mg (...) metabolic condition: Weight change > 5 kg in the last three months, diabetes with poor glycemic control (HgbA1c > 9.5% or FPG > 250 mg/dl), introduction of an anti-obesity drug/malabsorptive or restrictive bariatric (weight loss) surgery in the past 6 months prior to screening. History of gastrointestinal malabsorptive bariatric surgery within less than 5 years or ingestion of drugs known to produce hepatic steatosis including corticosteroids, high-dose estrogens, methotrexate, tetracycline

2018 Clinical Trials

173. Foot Intervention Study Utilizing Commercially Available Infrared Thermometers With Individuals With Diabetes

terms: Layout table for MeSH terms Diabetic Foot Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Foot Ulcer Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies (...) the intervention; Phase 2, a six-month RCT will assess the effectiveness of a CAIT; Phase 3, interviews will be conducted with participants, family and support persons, and health providers to explore their experiences with the intervention. Condition or disease Intervention/treatment Phase Diabetic Foot Device: Education and Thermometer Group Other: Education Only Group Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 71

2018 Clinical Trials

174. Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells to Non-healing Diabetic Foot Wounds

Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: No Keywords provided by Steno Diabetes Center: diabetes Additional relevant MeSH terms: Layout table for MeSH terms Diabetic Foot Foot Ulcer Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic (...) First Posted : April 26, 2018 Last Update Posted : June 6, 2018 See Sponsor: Steno Diabetes Center Collaborator: Leiden University Medical Center Information provided by (Responsible Party): Steno Diabetes Center Study Details Study Description Go to Brief Summary: examine safety of topical application of single dose allogeneic bone marrow derived mesenchymal stromal cells to non-healing diabetic foot ulcers Condition or disease Intervention/treatment Phase Diabetic Foot Ulcer Biological

2018 Clinical Trials

175. Dual Field PEMF Therapy in Lower Extremity Painful Diabetic Distal Symmetric Peripheral Neuropathy

period (4 months). Part B is a 8-month open-label active treatment extension period designed to collect longer-term data on pain, medication use, quality of life and safety (Part B).Part B of this trial is a an extension period upon completion of Part A. Condition or disease Intervention/treatment Phase Diabetic Nephropathy Device: Active Provant Therapy System Device: Inactive (sham) Provant Therapy System Not Applicable Study Design Go to Layout table for study information Study Type (...) significant foot deformity Skin condition that could alter peripheral sensations Previous surgery to the spine or lower extremity with residual symptoms of pain or difficulty with movement. Clinically significant arthropathy Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier

2018 Clinical Trials

176. Bone Health After Bariatric Surgery in Patients With Type 2 Diabetes

on the benefits and risks of each bariatric procedure. It will also help identify factors that could be tested to prevent or treat bone fragility in people with type 2 diabetes. Condition or disease Intervention/treatment Bariatric Surgery Bone Health Obesity, Morbid Diabetes Mellitus, Type 2 Procedure: Bariatric surgery Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 125 participants Observational Model: Cohort Time Perspective: Prospective Official (...) Gagnon, Dr, CHU de Quebec-Universite Laval ClinicalTrials.gov Identifier: Other Study ID Numbers: MP-10-2018-2957 First Posted: March 7, 2018 Last Update Posted: April 17, 2018 Last Verified: April 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Diabetes Mellitus, Type 2 Obesity, Morbid Glucose Metabolism Disorders Metabolic Diseases

2018 Clinical Trials

177. Relation of Epicardial Fat and Diabetic Nephropathy in Egyptian Patients

. Epicardial fat is located between the outer wall of the myocardium and the visceral layer of pericardium. Condition or disease Type2 Diabetes Mellitus Detailed Description: The epicardial fat layer originates from mesothelial cells and hence obtains its vascular supply from the coronary arteries. Much of the importance within the epicardial fat is its anatomical closeness to the myocardium and the fact that the two tissues share the same microcirculation. Epicardial fat is a metabolically active organ (...) for additonal information Responsible Party: Mohamed Abdel-Azeem Mohamed, Principle investigator, Assiut University ClinicalTrials.gov Identifier: Other Study ID Numbers: EPICARDIALNEPHRO First Posted: March 20, 2018 Last Update Posted: March 20, 2018 Last Verified: March 2018 Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Diabetes Mellitus, Type 2 Diabetic Nephropathies Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Kidney Diseases Urologic Diseases

2018 Clinical Trials

178. Using mHealth to Modernize Diabetes Care

. The MIMOSA is designed to be used alongside the camera that is built into the participants' cell phone, and the investigators will use a cell phone to take a picture of the participants' skin. This picture will tell us how much oxygen is getting to the participants' wound, which can tell us more about how the participants are healing. The MIMOSA device is an experimental diagnostic tool, and will not influence how the participants' wound is healing. Condition or disease Intervention/treatment Diabetic (...) terms Diabetic Foot Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Foot Ulcer Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies

2018 Clinical Trials

179. A Study Measuring the Effectiveness of Combined Modulated Ultrasound and Electric Current Stimulation as an Adjunctive Treatment in Treating Diabetic Foot Ulcers

Ulcer Pathologic Processes Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies Foot Diseases (...) with diabetic foot ulcers. Condition or disease Intervention/treatment Phase Diabetic Foot Ulcer Device: BRH-A2 wound healing device Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 50 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Participants will be randomly allocated into an experimental arm and a control arm of the study. The experimental group

2018 Clinical Trials

180. Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes

maximal beta-cell rest, and dietician support to promote dietary habits that minimize the likelihood of bacterial reflux from the duodenum to the pancreatic duct, will lead to preservation of beta cell function. This trial will examine whether the AIDIT protocol initiated within one week from diagnosis could preserve insulin production in children with Type 1 Diabetes. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 1 Diabetes Mellitus Metabolic Disease Glucose Metabolism (...) Disorders Endocrine System Diseases Juvenile Diabetes Insulin Dependent Diabetes Type 1 Diabetes Mellitus Inflammation Diet Modification Drug: Azithromycin Monohydrate Drug: Insulin Lispro Behavioral: Dietician support Phase 2 Detailed Description: The study is a 2-arm, randomized, open, single center, clinical trial. Eligible patients with type 1 diabetes will be randomized to the AIDIT protocol or treatment as usual (TAU). All patients diagnosed with T1D and included in the study will receive standard

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>